Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-mutated Acute Myeloid Leukemia

Documenti analoghi

• The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML
  di: Qiao, Xinan, et al.
  Pubblicazione: (2021)
• The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia
  di: Li, Xinyu, et al.
  Pubblicazione: (2020)
• Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation
  di: Liu, Fangbing, et al.
  Pubblicazione: (2020)
• Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia
  di: Luedtke, Daniel A., et al.
  Pubblicazione: (2020)
• Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia
  di: Brinton, Lindsey T., et al.
  Pubblicazione: (2020)